Back to Search
MELANIE CLEMONS, PH.D.
PH.D.
Family Psychologist
NPI: 1841423332Individual
Specialties, Licenses & Credentials
Family PsychologistPrimary
Psychologist — Family
Code: 103TF0000X
PSY 24578(CA)
Clinical Child & Adolescent Psychologist
Psychologist — Clinical Child & Adolescent
Code: 103TC2200X
PSY 24578(CA)
Research & Publications (20)
Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?
PMID 19299408·Ann Oncol·2009
3-trial
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22.
PMID 19097882·Eur J Cancer·2009
8-other
A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy.
PMID 17473981·Breast Cancer Res Treat·2008
3-trial
Identifying menopause in breast cancer patients: considerations and implications.
PMID 17061039·Breast Cancer Res Treat·2007
6-review
Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
PMID 17001071·J Clin Oncol·2006
3-trial
Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer.
PMID 16549806·Oncologist·2006
6-review
Can bone markers guide more effective treatment of bone metastases from breast cancer?
PMID 16319976·Breast Cancer Res Treat·2006
6-review
O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts.
PMID 16278661·Br J Cancer·2005
7-preclinical
Should oral bisphosphonates be standard of care in women with early breast cancer?
PMID 15830146·Breast Cancer Res Treat·2005
6-review
Perspectives on the future of bisphosphonate use in breast cancer patients.
PMID 15490383·Semin Oncol·2004
6-review
Do physicians follow systemic treatment and funding policy guidelines?
PMID 15300959·Can J Clin Pharmacol·2004
4-observational
Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?
PMID 15145507·Cancer Treat Rev·2004
6-review
Should all breast cancer patients with symptomatic bone metastases be treated with bisphosphonates? The case in support.
PMID 15074732·Clin Oncol (R Coll Radiol)·2004
5-case
Management of recurrent locoregional breast cancer: oncologist survey.
PMID 14659148·Breast·2003
4-observational
Pharmacokinetic, biochemical and clinical effects of dimethyltriazenoimidazole-4-carboxamide-bischloroethylnitrosourea combination therapy in patients with advanced breast cancer.
PMID 12494480·Int J Cancer·2003
8-other
Heterogeneity of O6-alkylguanine DNA-alkyltransferase expression in human breast tumours.
PMID 12087469·Br J Cancer·2002
8-other
Does treatment at the time of locoregional failure of breast cancer alter prognosis?
PMID 11319847·Cancer Treat Rev·2001
6-review
Locoregionally recurrent breast cancer: incidence, risk factors and survival.
PMID 11319846·Cancer Treat Rev·2001
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 470 27TH ST, BAWAR
OAKLAND, CA 94612 - Phone
- (510) 982-6765
Quick Facts
- NPI
- 1841423332
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile